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ABSTRACT
‘Beauty lies in the eyes of the beholder’. Beauty has been admired
since time immemorial not only by the medical personals but
also by the general masses. Beauty undoubtedly has a strong
influence on human life. Orthodontists have a special interest in
facial beauty. One of the most socially significant of human
behaviors is expression of emotions on the face with smile being
the most important of those emotions. The display of excessive
gingival tissue in the maxilla upon smiling has been called a
‘gummy smile’, a condition some consider esthetically displeasing.
Some people with excessive gingival display are self-conscious
or embarrassed about it, and some are psychologically affected.
There are a number of different treatment methods described in
the literature for the treatment of gummy smile. These includes
both surgical and nonsurgical options, including Le Fort I
osteotomy, crown lengthening procedure, maxillary incisor
intrusion, self-curing silicone implant injected at the anterior nasal
spine and finally myectomy and partial resection of the levator
labii superioris or muscle repositioning. Some patients do not
wish to go through the long presurgical orthodontic treatment in
preparation for a Le Fort I osteotomy while others wish to avoid
the possible complications surrounding surgery, such as post-
operative pain, swelling and infection, permanent or temporary
nerve damage and root damage during osteotomy. A nonsurgical
alternative for reducing excessive gingival display caused by
muscle hyperfunction would be advantageous. Botulinum toxin
has been under clinical investigation since the late 1970s for the
treatment of several conditions associated with excessive muscle
contraction or pain. The aim of this article is to give an overview
about the science of Botox and its various uses.
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INTRODUCTION
The writer Margaret Wolfe Hungerford (1878) famously said
‘Beauty lies in the eyes of the beholder’.
Beauty has been admired since time immemorial not only
by the medical personals but also by the general masses, but
the quantification of beauty is always subjective because beauty
is interpreted not just on esthetic values but also on the taste
of an individual.1 Perceptions of facial beauty are
multifactorial, with genetic, environmental and cultural
foundations.2 Beauty can be defined as a combination of
qualities that give pleasure to the senses or to the mind.
Esthetics is the study of beauty and, to a lesser extent, its
opposite, the ugly.
The term esthetics, derives from the German ästhetisch
or the French esthétique, both derived from the Greek
aisthetikos ‘esthetic-sensitive-sentient’. Esthetics as
perceived generally is not just the ability to discriminate at a
sensory level. It goes beyond the sensory level. As delicacy
of taste is not merely ‘the ability to detect all the ingredients
in a composition’, the judgment of beauty is based on sensory,
emotional and intellectual all at once.
Beauty undoubtedly has a strong influence on human life.
According to Shakespeare, ‘Beauty itself doth of itself
persuade the eyes of men without an orator.’ The philosopher
Pascal commented, ‘Had Cleopatra’s nose been shorter, the
whole face of the world would have changed!’ From Homer’s
Helen of Troy, whom the poet Christopher Marlowe described
as having a ‘face that launched a thousand ships’, to Queen
Nefertiti, whose name literally means the ‘Perfect One’, to
modern models and actors, facial beauty has always been the
most valued aspect of human beauty.
Orthodontists have a special interest in facial beauty as
Wahl3 wrote, ‘Now it appears that facial esthetics is again in
the forefront as we realize why patients come to us in the first
place’. One of the most socially significant of human behaviors
is expression of emotions on the face with smile being the
most important of those emotions. ‘The smile is the most
recognizable signal in the world. Smiles are such an important
part of communication that we see them far more clearly than
any other expression. We can pick up a smile at 300 feet – the
length of a football field’.4 Just as a nice smile can act as a
powerful communication tool, an unpleasing smile can have
the equally powerful negative impact and this is often one of
the reasons why patients seek orthodontic treatment. The
display of excessive gingival tissue in the maxilla upon smiling
has been called a ‘gummy smile’, a condition some consider
esthetically displeasing. Some people with excessive gingival
display are self-conscious or embarrassed about it, and some
are psychologically affected. Etiologic factors can be skeletal,
gingival, muscular, iatrogenic or some combination of these.
The literature contains many reports that address the skeletal
problem of vertical maxillary excess5-8 and gingival problems
related to delayed passive eruption.9,10 The muscular capacity
to raise the upper lip higher than average (hyperfunctional
muscle) can cause excessive gingival display.11 Upper lip
elevator muscles include the levator labii superioris, levator
labii superioris alaeque nasi, levator anguli oris, zygomaticus
major, zygomaticus minor and the depressor septi nasi. There
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are a number of different treatment methods described in the
literature for the treatment of gummy smile. These includes
both surgical and nonsurgical options including; Le Fort I
osteotomy, crown lengthening procedure, maxillary incisor
intrusion, self-curing silicone implant injected at the anterior
nasal spine and finally myectomy and partial resection of the
levator labii superioris or muscle repositioning. Some patients
do not wish to go through the long presurgical orthodontic
treatment in preparation for a Le Fort I osteotomy. Others
wish to avoid the possible complications surrounding surgery
such as postoperative pain, swelling and infection, permanent
or temporary nerve damage, root damage during osteotomy,
surgical and/or orthodontic relapse, possible need for blood
transfusion and finally a less than optimal occlusal outcome.12,13
A nonsurgical alternative for reducing excessive gingival
display caused by muscle hyperfunction would be
advantageous. Botulinum toxin has been under clinical
investigation since the late 1970s for the treatment of several
conditions associated with excessive muscle contraction or
pain.14
The aim of this article is to give an overview about the
science of Botox and its various uses.
A Brief History of Turning Back Time with
Botulinum Toxins
Botulinum toxins have formed the foundation of minimally
invasive esthetic facial treatments, beginning with their use to
smooth glabellar frown lines and expanding to include other
facial areas as well as combination use with other minimally
invasive agents and procedures.
The observation that botulinum toxin smoothed facial lines
when used therapeutically led researchers to study the toxin’s
effect on glabellar frown lines. In 1992, the first published
esthetic study on botulinum toxin established that botulinum
toxin type A safely and effectively diminished the appearance
of glabellar lines.15 Additionally, large scale, randomized,
controlled trials documented safety and efficacy, leading to
the approval by the United States Food and Drug
Administration (FDA) of the first botulinum toxin for cosmetic
use in 2002.16 It was used in 2005 on patients with
hyperfunctional upper lip elevator musculature to correct a
gummy smile and to establish the optimal minimal dose of
BTX-A needed to obtain cosmetically pleasing results.17
The Science of Botulinum Toxins: Composition
and Pharmacology
Botulinum toxins occur in seven known serotypes labeled A-G
produced by different strains of Clostridium botulinum.18
Clinically important biologic activity, particularly in the
cosmetic arena, is limited primarily to the type A serotype,
although a type B formulation is approved in several
countries for treating cervical dystonia. Although botulinum
toxin type B has been studied for cosmetic use, it generally
elicits more pain upon injection and has been found to have
a faster onset but shorter duration of action than the type A
serotype.19,20 Therefore, this review will be restricted to
products containing botulinum toxin type A. Botox (Allergan,
Irvine, Calif) is a purified BTX-A isolated from the
fermentation of C. botulinum. It is a stable, sterile, vacuum-
dried powder that is diluted with saline solution without
preservatives. BTX-A weakens skeletal muscles by cleaving
the synaptosome-associated protein SNAP-25, thus blocking
the release of acetylcholine from the motoneuron and enabling
the repolarization of the postsynaptic terminal. As a result,
the muscular contraction is blocked. The production of
acetylcholine is not affected by this blockade of the
neuromuscular transmission. The effects last 3 to 6 months,
although some investigators have reported a longer duration
in patients exposed over a prolonged period of time.
Pharmacokinetics
Botulinum toxin type A is not expected to be present in the
peripheral blood at measurable levels following intramuscular
injection at the recommended doses. The recommended
quantities of neurotoxin administered at each treatment session
are not expected to result in systemic, overt distant clinical
effects, i.e. muscle weakness, in patients without other
neuromuscular dysfunction. However, subclinical systemic
effects have been shown by single-fiber electromyography
after intramuscular doses of botulinum toxins appropriate to
produce clinically observable local muscle weakness.
Uses
BTX-A has been used to treat strabismus,21 (visual problem in
which the eyes are not aligned properly and points in different
directions. Botox is thought to affect muscle pairs inducing
an atropic lengthening of the injected muscle and a
corresponding shortening of the muscle antagonist)  cervical
dystonia,22 blepharospasm and hemifacial spasm,23
hyperfunctional larynx,24 juvenile cerebral palsy,25 spasticity,26
pain and headache,27 occupational dystonia and writer’s
cramp,28 temporomandibular disorders,29 myofacial pain,30 and
oromandibular dystonia and bruxism,31 and gummy smile.
Contraindications
Botox is contraindicated in the presence of infection at the
proposed injection site(s) and in individuals with known
hypersensitivity to any ingredient in the formulation.
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Precautions
The safe and effective use of Botox depends upon proper
storage of the product, selection of the correct dose, and proper
reconstitution and administration techniques. An understanding
of standard electromyographic techniques is also required for
treatment of strabismus and may be useful for the treatment
of cervical dystonia.
Caution should be used when botox treatment is used in
the presence of inflammation at the proposed injection site(s)
or when excessive weakness or atrophy is present in the target
muscle(s).
Drug Interactions
Coadministration of Botox and aminoglycosides or other
agents interfering with neuromuscular transmission (e.g.,
curare-like compounds) should only be performed with
caution as the effect of the toxin may be potentiated.
The effect of administering different botulinum neurotoxin
serotypes at the same time or within several months of each
other is unknown.
Excessive neuromuscular weakness may be exacerbated
by administration of another botulinum toxin prior to the
resolution of the effects of a previously administered
botulinum toxin.
Pregnancy: Pregnancy Category C
When pregnant mice and rats were injected intramuscularly
during the period of organogenesis, the developmental NOEL
(No-observed-effect-level) of botox was 4 U/kg. Higher doses
(8 or 16 U/kg) were associated with reductions in fetal body
weights and/or delayed ossification which may be reversible.
In a range finding study in rabbits, daily injection of 0.125
U/kg/day (days 6 to 18 of gestation) and 2 U/kg (days 6 and
13 of gestation) produced severe maternal toxicity, abortions
and/or fetal malformations. Higher doses resulted in death of
the dams. The rabbit appears to be a very sensitive species to
Botox.
There are no adequate and well-controlled studies of Botox
in pregnant women. Because animal reproductive studies are
not always predictive of human response, Botox should be
administered during pregnancy only if the potential benefit
justifies the potential risk to the fetus. If this drug is used
during pregnancy, or if the patient becomes pregnant while
taking this drug, the patient should be apprised of the potential
risks, including abortion or fetal malformations which have
been observed in rabbits.
Carcinogenesis, mutagenesis, impairment of fertility:
Long-term studies in animals have not been performed to
evaluate carcinogenic potential of Botox.
Nursing Mothers
It is not known whether this drug is excreted in human milk.
Because many drugs are excreted in human milk, caution
should be exercised when botox is administered to a nursing
woman.
Pediatric Use
Safety and effectiveness in children below the age of 12 have
not been established.
Geriatric Use
Clinical studies of botox did not include sufficient numbers
of subjects aged 65 and over to determine whether they respond
differently from younger subjects. Other reported clinical
experience has not identified differences in responses between
the elderly and younger patients. In general, dose selection
for an elderly patient should be cautious, usually starting at
the low end of the dosing range, reflecting the greater
frequency of decreased hepatic, renal or cardiac function and
of concomitant disease or other drug therapy.
Adverse Reactions
Skin rash (including erythema multiforme, urticaria and
psoriasiform eruption), pruritus and allergic reaction.16
In general, adverse events occur within the first week
following injection of Botox while generally transient may
have a duration of several months. Localized pain, tenderness
and/or bruising may be associated with the injection. Local
weakness of the injected muscle(s) represents the expected
pharmacological action of botulinum toxin. However,
weakness of adjacent muscles may also occur due to spread
of toxin.
Immunogenicity
Formation of neutralizing antibodies to botulinum toxin
type A may reduce the effectiveness of Botox treatment by
inactivating the biological activity of the toxin. The rate of
formation of neutralizing antibodies in patients receiving
Botox has not been well studied.
Dosage and Administration
Botox is supplied in a single use vial. Because the product and
diluent do not contain a preservative, once opened and
reconstituted, store in a refrigerator and use within 4 hours.
Any remaining solution has to be discarded. Do not freeze
reconstituted Botox.
Botox is to be reconstituted with sterile, nonpreserved
saline prior to intramuscular injection.
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Vial Size
There are two sizes of vials available in India, 100 and 50 units.
The former contains 100 units (U) of Clostridium botulinum
toxin type A, 0.9 mg of sodium chloride in a sterile, 0.5 mg of
human serum albumin, in vacuum-dried form without a
preservative.
Reconstitution
To reconstitute vacuum-dried Botox® (Botulinum toxin
type A), use sterile normal saline without a preservative; 0.9%
sodium chloride Injection is the recommended diluent. For a
100 unit pack, use 2.5 ml of saline so that each 0.1 ml contains
4 units of Botox®. Draw up the proper amount of diluent in
the appropriate size syringe. Since, Botox® is denatured by
bubbling or similar violent agitation, inject the diluent into
the vial gently. Discard the vial if a vacuum does not pull the
diluent into the vial. Record the date and time of reconstitution
on the space provided on the label. Once, a bottle of Botox®
is reconstituted, it should be used within 4 hours. During this
time period, reconstituted Botox® should be stored in a
refrigerator (2-8°C). However, recent studies have shown that
once refrigerated, it can be used till 6 weeks.
Dosage
The dosage of Botox® varies for each injection site, the extent
of the facial lines and the mass of the muscle.
Frown lines : 20 to 25 units.
Crows feet : 12 units per eye, i.e. 24 units in
total
Forehead lines : 16 to 20 units
Bunny lines : 4 to 8 units
Masseter hypertrophy : 25 units on each side of the jaw,
i.e. in total 50 units
Hyperhidrosis : 25 units in each palm, i.e. 50 units
in total.
Botox® offers sustained relief, dose after dose. The effect
of the first treatment lasts up to 4 months. The treatment can
be continued as long as the treatment symptoms respond to
Botox® therapy. Usually, Botox® treatment is required
approximately 3 times a year. Since symptoms can change
overtime, the amount and duration of relief can vary. Also the
dosage may change based on the severity of the condition and
the indication for which it has to be administered.
For the treatment of gummy smile a dose of 1.25 U per
muscle site per side was selected as a baseline.17 Under sterile
conditions, 1.25 U per side should be injected in both the right
and left levator labii superioris and levator labii superioris
alaeque nasi muscles (LLS), and an additional 1.25 U per side
at the overlap areas of the levator labii superioris and
zygomaticus minor muscles (LLS/ZM).
CONCLUSION
Although surgical techniques have been reported in the
literature, they are not routinely used to treat hyperfunctional
upper lip elevator muscles resulting in a short upper lip and a
concomitant gummy smile. Most of the surgical correction
currently used seems to be Le Fort I maxillary osteotomies
with impaction for skeletal vertical maxillary excess and
gingivectomies for delayed passive dental eruption with
excessive gingival display. Because BTX-A is used frequently
for the temporary correction of perioral rhytides, care should
be taken when injecting these anatomical areas in patients with
hypotonic, flaccid lips to avoid further muscle weakening and
an esthetically unacceptable smile because of excessive soft
tissue covering the smile line.
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